The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms - PubMed
3 hours ago
- #GLP-1
- #Obesity Treatment
- #Dual Agonist
- GLP-1-based therapies have revolutionized obesity treatment.
- GLP-1 receptor agonists like semaglutide show significant efficacy, with central mechanisms of action.
- Tirzepatide (GLP-1R/GIPR dual agonist) and maridebart cafraglutide (GLP-1RA/GIPR antagonist) both produce beneficial metabolic effects.
- GIPR agonism or antagonism alone lacks evidence for anorectic effects in humans.
- GLP-1R/GIPR dual targeting compounds are more effective than semaglutide due to other reasons beyond GIPR action.